Global Medical Imaging Phantoms Market Size, Trend & Opportunity Analysis Report, by Application (Calibration & Quality Assurance, Diagnostic Imaging, Research & Development, Training & Education, Therapeutic Applications), Product (CT (Computed Tomography) Phantoms, MRI (Magnetic Resonance Imaging) Phantoms, Ultrasound Phantoms, X-ray Phantoms, Nuclear Medicine Phantoms, Others), End-use (Hospitals & Diagnostic Imaging Centersm, Medical Device Manufacturers, Others), and Forecast, 2025-2035
Global Medical Imaging Phantoms Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Medical Imaging Phantoms Market was valued at USD 181.5 million in 2024 and is anticipated to reach USD 348.13 million by 2035, expanding at a CAGR of 6.1% during the forecast period 2025-2035. Calibration at its best function of medical imaging phantoms. They hold a crucial place for clinicians and researchers, ensuring accurate imaging systems with less live testing. Like everything else in radiology, phantoms have emerged as the unsung heroes of medical imaging precision-with the advent of AI-assisted diagnostics, hybrid modalities, and value-driven imaging workflows. Severe pressure is being thrust upon healthcare systems globally to meet safety and quality standards while improving their sharper, reproducible diagnostic outputs. This scenario has further expedited the push for imaging phantoms across MRI, CT, PET, and ultrasound, hybrid modalities in the world as quality and standardisation assets.
Quality frontiers, the importance of phantoms now extends into innovation. Medical research infrastructures and device manufacturers make extensive use of phantoms in not only validating new operating protocols of imaging but also assessing reconstruction algorithms powered by artificial intelligence and creating technologies being developed, like photon-counting CT or advanced molecular imaging. As healthcare progresses in shifting towards more personal diagnostics, phantoms evolve and develop into sophisticated surrogates that accurately replicate human tissue heterogeneity for high-fidelity simulations of real-world imaging scenarios.
Increasing demand for non-invasive procedures coupled with an increase in R&D investments, the manufacturers of these devices have been compelled to develop high-efficiency phantoms capable of replicating complex anatomical structures while including traceable calibration features. The new era of precision in healthcare currently drives a very energetic wave of innovation and competition, as companies strive to integrate ingenuity with regulatory compliance as they prepare for the next generation of imaging-validation tools.
Recent Developments in the Industry
- In January 2024, Kyoto Kagaku introduced the next generation of multi-modality phantoms that reproduce ultra-realistic tissue properties for CT, MRI, and ultrasound. This innovation allows radiology trainees and clinical researchers to develop skills and standardise diagnostic practices.
- In July 2024, CIRS Inc. (a Sun Nuclear Company) released AI-ready phantom solutions tailored for validating deep learning models in diagnostic imaging. These phantoms provide traceable references for algorithm benchmarking, ensuring robustness and reliability in machine learning applications.
- In April 2023, PTW Freiburg GmbH presented a next-generation dosimetry phantom designed for combined radiotherapy-imaging applications. This development considers the growing need for hybrid treatment workflows and allows for the precise monitoring of doses supported by real-time imaging.
- In February 2024, Biodex Medical Systems Inc. (a Mirion Technologies company) partnered with leading distributors in Europe to strengthen the availability of its ultrasound and nuclear medicine phantoms, responding to increasing regional demand for quality assurance solutions.
- In March 2025, Modus Medical Devices Inc. announced a focused research investment to develop new phantom models for photon-counting CT systems, set to revolutionise diagnostic imaging resolution and clinical efficiency.
Market Dynamics
Steady phantom demand across healthcare settings is fuelled by increasing adoption of diagnostic imaging.
Demand for diagnostic imaging is increasing, substantially because of an ageing population and chronic diseases, resulting in a rapidly rising reliance on precision-based medicine. Imaging phantoms are an integral part of calibration and validation in hospitals or diagnostic centres to allow adherence to very refined standards of image quality and safety of patients with all kinds of modality integration.
Regulatory push drives innovation in phantom design and quality assurance systems.
Phantom use has become an inevitable part of today for routine system validation and clinical trial imaging with stringent compliance from the FDA, EMA, and ISO. Manufacturers invest in the most modern materials that replicate those of real tissue densities and incorporate even traceable calibration markers. It clearly shows that the industry now strives for a highly specialised, regulatory-compliant design in phantoms that are accurate as well as durable.
Growing R&D investments nurture the phantom of imaging modalities.
In the last few decades, research organisations, as well as manufacturers of imaging equipment, have been spending most of their research resources on phantoms, because new technologies-development-from artificial intelligence image analysis, particle-counting CTs, to molecular imaging-need phantoms that can reproduce human tissue complexities in considerable fidelity. Today's status of phantoms as a really enabling factor of imaging innovation is recognised.
Material and cost limitations, therefore, prove to be obstructions towards adoption in such economies.
While the advanced phantoms are being adopted by developed markets, it does not include their high price and limited local manufacturing capabilities, thus restricting their usage in price-sensitive regions. Barriers to importation-which are aggravated by supply chain constraints-pose some of the major problems to the smaller diagnostic centres in Asia, Africa, and Latin America.
Emerging prospects for phantom applications after the shift toward hybrid and personalised imaging.
The future of next-generation phantoms is being created in this fertile ground since radiology, nuclear medicine, and AI are converging. In this case, the hybrid imaging phantoms for validating protocols across modalities or those involving patient-specific anatomical models for personalised treatment planning promise to provide tremendous opportunities for transformative growth.
Attractive Opportunities in the Market
- AI-Driven Imaging Validation - Development of AI-ready phantoms accelerates algorithm benchmarking for diagnostic accuracy.
- Photon-Counting CT Phantoms - Emerging demand for validation models tailored to ultra-high-resolution CT technology.
- Hybrid Therapy Support - Phantom designs for combined radiotherapy-imaging workflows enable cross-disciplinary treatment precision.
- 3D Printed Custom Phantoms - Personalised phantom manufacturing delivers anatomically accurate models for clinical trial support.
- Eco-Friendly Phantom Materials - Use of sustainable, biocompatible materials reduces environmental and manufacturing footprint.
- Emerging Market Expansion - Growing healthcare investment in Asia-Pacific and Latin America drives phantom adoption.
- Academic-Industry Partnerships - Collaborations between universities and manufacturers accelerate innovation in phantom development.
- Training and Education Surge - Phantoms are increasingly utilised for skill development and radiology workforce training.
- Regulatory Compliance Growth - Heightened global imaging standards reinforce phantom integration into QA protocols.
- R&D Commercialisation Pathways - Translating phantom-based prototypes into scalable imaging solutions opens new revenue streams.
Report Segmentation
By Application: Calibration & Quality Assurance, Diagnostic Imaging, Research & Development, Training & Education, Therapeutic Applications
By Product: CT (Computed Tomography) Phantoms, MRI (Magnetic Resonance Imaging) Phantoms, Ultrasound Phantoms, X-ray Phantoms, Nuclear Medicine Phantoms, Others
By End-use: Hospitals & Diagnostic Imaging Centersm, Medical Device Manufacturers, Others
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Kyoto Kagaku Co., Ltd., CIRS Inc. (a Sun Nuclear Company), PTW Freiburg GmbH, Biodex Medical Systems Inc. (Mirion Technologies), Gammex Inc., Modus Medical Devices Inc., PhantomX, Leeds Test Objects Ltd., True Phantom Solutions Inc., and RTI Group.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 295
Dominating Segments
Regulatory and imaging system accuracy requirements, that calibration and quality assurance dominate.
Calibration and quality assurance are the primary users of phantoms, as regulatory requirements demand that systems are validated regularly around the world to guarantee image accuracy and patient safety. Phantoms for calibration made for CT, MRI, ultrasound, and PET/CT systems ensure reproducibility of performance in diagnostic environments. These phantoms are being used at hospitals and in diagnostic centres to meet the global regulatory requirements, especially together with the increasing sophistication and integration of the imaging techniques.
Diagnostic Imaging segment has increased tremendously, with advanced imaging modalities gaining demand.
Diagnostic imaging has grown to an unimaginable extent under the pressure of an ageing demographic and the rise of chronic diseases. Phantoms in this area allow radiologists to standardise imaging protocols, train workforce personnel, and start validating new imaging algorithms. Hybrid systems such as PET/MRI and photon-counting CT are growing the scope of phantoms even further, since these new modalities require more elaborate tools for validation.
R&D applications are gradually on the rise as phantoms become crucial for medical innovation.
Phantoms are gaining valuable traction in the R&D environment towards the advancement of new imaging hardware, reconstruction algorithms, and standardisation of clinical trials. From AI-based diagnostic models to next-generation imaging modalities, phantoms provide the reproducible testing conditions that are so vital in clinching the transfer of theoretical research into clinical applications. The use of phantoms in academic-industrial partnerships is also on the rise, with universities and manufacturers collaborating to develop customised phantoms that imitate patient-specific anatomical structures.
Key Takeaways
- Calibration Leadership - QA phantoms dominate due to their indispensability in compliance and accuracy assurance.
- Diagnostic Growth Surge - Expanding imaging demand boosts phantom usage in hospitals and diagnostic centres worldwide.
- R&D Expansion - Research institutions increasingly adopt phantoms for AI, photon-counting CT, and hybrid imaging.
- Innovation Catalyst - Phantoms drive progress in imaging protocol development and AI validation.
- Regulatory Compliance Push - Global safety and quality standards necessitate phantom integration across imaging workflows.
- Training Demand Growth - Medical education relies heavily on phantoms for skill-building and protocol standardisation.
- Material Innovation Trends - Sustainable, biocompatible materials reshape phantom development and reduce ecological impact.
- Emerging Market Opportunities - Investments in Asia-Pacific and Latin America bolster phantom adoption.
- Hybrid Imaging Adoption - Cross-modality phantoms gain importance as radiology converges with nuclear medicine.
- Collaborative R&D Pathways - Joint academic-industry initiatives accelerate the development of next-generation phantoms.
Regional Insights
North America leads in the market as a result of strong regulatory compliance and advanced healthcare infrastructure.
North America is the foremost region in the medical imaging phantoms market as it boasts of strong healthcare systems, the most extensive adoption of imaging techniques, and a demanding regulatory environment. Particularly, the U.S., where it is a major hub for innovation in imaging, supported by wide-ranging research and development pipelines lined up with FDA regulations, allows phantoms to be part of the system validation. Increased demand for AI-based diagnostic solutions has put more weight on phantoms to maintain confidence and reproducibility.
Europe innovates with green and advanced phantom design regulations under strong regulation.
Europe is, therefore, the first user of phantoms, all due to its strict regulation in this respect, and coupled with the EU's effort to direct harmonised health care standards across the continent. Germany, the UK, and France are active participants, with rising investments in green materials and multi-modality designs for phantoms. Much collaboration between university and industry players is taking place to scale up the increasing demand for hybrid imaging and AI validation, both in clinical and research settings.
Asia-Pacific is the fastest-growing region with an increasing capability in imaging and local innovation.
Asia-Pacific emerges as the fast-growing regional market due to increased investment in healthcare, improved imaging infrastructure, and the establishment of domestic phantom manufacturing capabilities. China, India, and South Korea are adopting such governments' encouragement policies on training and innovation regarding diagnostic imaging. High patient numbers and continuing research activity will provide a more balanced future for clinical and educational applications of phantoms.
LAMEA is gradually strengthening adoption amid investments in healthcare and regional training programs.
The three regions of Latin America, the Middle East, and Africa are now incrementally adopting medical imaging phantoms due to healthcare modernisation efforts and increased investments in diagnostic infrastructure. Lack of cost-effective equipment was a barrier to use in some areas, but other initiatives to advance radiology training and regulatory alignment foster increased phantom use. Global partnerships further help close accessibility and innovation gaps.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
The Calibration and Quality Assurance (QA) segment is the dominant application. This leadership is driven by stringent global regulatory requirements (such as FDA, EMA, and ISO) that mandate regular system validation to ensure image accuracy, reproducibility, and patient safety across various modalities like CT, MRI, and ultrasound.
AI is a major catalyst for innovation, leading to the development of "AI-ready" phantoms. These specialized tools, such as those released by CIRS Inc. in 2024, provide traceable references for benchmarking deep learning models and validating reconstruction algorithms, ensuring the robustness of machine learning applications in diagnostics.
Key drivers include the rising global demand for diagnostic imaging due to aging populations and chronic diseases, the shift toward precision-based medicine, the emergence of hybrid imaging modalities (like PET/MRI), and the increasing need for high-fidelity surrogates to test next-generation technologies like photon-counting CT.
North America currently leads the market due to its advanced healthcare infrastructure and strict regulatory environment. However, the Asia-Pacific region is the fastest-growing market, fueled by increased healthcare investments, expanding imaging capacity, and the development of domestic manufacturing capabilities in countries like China and India.
The primary obstacles include the high cost of advanced phantoms and limited local manufacturing in price-sensitive regions. Additionally, material limitations in replicating complex human tissue heterogeneity and supply chain constraints in LAMEA (Latin America, Middle East, and Africa) pose challenges for smaller diagnostic centers.
Phantoms are considered essential enabling factors for photon-counting CT. Manufacturers like Modus Medical Devices Inc. are investing in new phantom models specifically designed to validate the ultra-high-resolution and clinical efficiency of these systems, which are set to revolutionize diagnostic imaging.
3D printing offers an attractive opportunity for the production of personalized, custom phantoms. This technology allows for the manufacturing of anatomically accurate models that mimic patient-specific structures, which is particularly valuable for clinical trial support and personalized treatment planning.
In early 2024, Kyoto Kagaku introduced next-generation multi-modality phantoms with ultra-realistic tissue properties. Additionally, PTW Freiburg GmbH launched a dosimetry phantom in 2023 specifically designed for hybrid radiotherapy-imaging workflows to monitor real-time radiation doses.
The market features several prominent players, including Kyoto Kagaku Co., Ltd., CIRS Inc. (Sun Nuclear), PTW Freiburg GmbH, Biodex Medical Systems Inc. (Mirion Technologies), Gammex Inc., Modus Medical Devices Inc., and the RTI Group. These companies are increasingly focused on academic-industry partnerships to accelerate R&D.
